Lisinopril vs Olmesartan for Hypertension
Both lisinopril (ACE inhibitor) and olmesartan (ARB) are equally recommended as first-line agents for hypertension according to current guidelines, with the choice primarily driven by tolerability rather than efficacy, though olmesartan may provide superior 24-hour blood pressure control and is preferred when sustained coverage is critical. 1, 2
When to Choose Each Agent
Choose Lisinopril When:
- Cost is a primary concern - Lisinopril is typically less expensive as a generic ACE inhibitor
- Patient has compelling indications for ACE inhibitors:
- Patient has no history of ACE inhibitor-related cough or angioedema
- Renal impairment is present - Lisinopril has well-established dosing adjustments for renal dysfunction 3
Choose Olmesartan When:
- Patient has ACE inhibitor-induced cough (occurs in 5-20% of patients on ACE inhibitors)
- Superior 24-hour blood pressure control is needed - Olmesartan demonstrates more sustained antihypertensive effect over 24 hours with better buffering of blood pressure variability 4, 5
- Patient has resistant hypertension - Olmesartan shows association with better blood pressure control in treatment-resistant cases 6
- Patient requires once-daily dosing reliability - Olmesartan provides more consistent trough-to-peak ratios 4, 5
Dosing Recommendations
Lisinopril Dosing 3:
- Initial dose: 10 mg once daily (standard); 5 mg once daily if on diuretics or elderly
- Usual maintenance range: 20-40 mg once daily
- Maximum dose: 80 mg once daily (though doses >40 mg show minimal additional benefit)
- Renal adjustment required:
- CrCl >30 mL/min: No adjustment
- CrCl 10-30 mL/min: Start at 5 mg once daily
- CrCl <10 mL/min or hemodialysis: Start at 2.5 mg once daily
Olmesartan Dosing (based on research evidence):
- Initial dose: 20 mg once daily
- Usual maintenance range: 20-40 mg once daily
- Maximum dose: 80 mg once daily for maximal renin-angiotensin system blockade 7
Combination Therapy Strategy
Current guidelines strongly recommend initial combination therapy for most patients with confirmed hypertension (BP ≥140/90 mmHg) rather than monotherapy. 1, 2
Preferred Combinations:
- Either lisinopril OR olmesartan + amlodipine (calcium channel blocker)
- Either lisinopril OR olmesartan + hydrochlorothiazide or chlorthalidone (thiazide diuretic)
- Use single-pill combinations when available to improve adherence 1, 2
Critical Pitfall to Avoid:
Never combine lisinopril with olmesartan (ACE inhibitor + ARB) - This dual RAS blockade significantly increases risk of cardiovascular events, kidney disease, and hyperkalemia without additional benefit 1, 2
Monitoring Considerations
For Both Agents:
- Baseline: Serum creatinine, potassium, blood pressure
- Follow-up (1-2 weeks after initiation or dose change):
- Serum creatinine and potassium (watch for hyperkalemia and acute kidney injury)
- Blood pressure response
- Ongoing: Monitor every 3-6 months once stable
Specific Monitoring for Lisinopril:
- Higher risk of angioedema - particularly in Black patients and those with history of angioedema
- Cough monitoring - occurs in 5-20% of patients, typically develops within first few months
- Twice-daily dosing is NOT more effective than once-daily dosing despite manufacturer labeling 8
Specific Monitoring for Olmesartan:
- Sprue-like enteropathy (rare but serious) - monitor for severe chronic diarrhea with weight loss
- Better 24-hour coverage means less white-coat effect at office visits 4, 5
Efficacy Comparison
Research demonstrates that olmesartan 20 mg provides superior blood pressure reduction compared to losartan 50 mg, valsartan 80 mg, and irbesartan 150 mg at recommended maintenance doses 4. While direct head-to-head trials of olmesartan vs lisinopril are lacking, both classes (ACE inhibitors and ARBs) show equivalent cardiovascular outcomes in large trials 1, 2.
The key differentiator is that olmesartan provides more sustained 24-hour blockade of the renin-angiotensin system, with 80 mg olmesartan achieving nearly complete 24-hour blockade comparable to combination ACE inhibitor + ARB therapy 7.
Special Populations
Elderly Patients:
- Start lower: Lisinopril 5 mg or olmesartan 10-20 mg
- Monitor for orthostatic hypotension carefully
- Both agents are effective and well-tolerated in elderly patients 9
Stage 2 Hypertension (BP ≥140/90 mmHg):
- Initiate combination therapy immediately rather than monotherapy 1, 2
- Preferred: RAS blocker (lisinopril or olmesartan) + calcium channel blocker or thiazide diuretic as single-pill combination
Resistant Hypertension:
- Olmesartan shows stronger association with blood pressure control in resistant cases 6
- Add aldosterone antagonist (spironolactone) as fourth agent if needed